For nearly 40 years, the Chevron Doctrine shaped how ambiguous federal laws were interpreted. Originating from Chevron U.S.A., Inc. v. Natural Resources Defense Council (1984), the doctrine held that, when a statute was ambiguous, courts should defer to a federal agency’s reasonable interpretation. Agencies were long understood to be the institutions best equipped to clarify statutory gaps, particularly in technical fields, such as public health, medicine, and environmental protection. Courts generally deferred to those agency interpretations, recognizing the value of scientific and subject-matter expertise.
That stabilizing framework has now been dismantled. In 2024, the Supreme Court’s decisions in Loper Bright Enterprises v. Raimondo and Relentless Inc. v. Department of Commerce formally ended Chevron deference. The shift arrives in the immediate aftermath of Dobbs v. Jackson Women’s Health Organization, fundamentally altering the landscape of reproductive health care regulation.
The combined effect is a regulatory environment where legal ambiguity persists, clinical uncertainty grows, and judges — rather than medical experts — serve as the primary interpreters of health-related statutory language.
How Chevron Once Stabilized Reproductive Health Regulation
When the Court issued Chevron in 1984, it recognized that the leadership and personnel of executive branch agencies possess specialized substantive and technical expertise that Congress lacks in the policy, evidentiary basis, and administrative procedures needed to address the subject matter for which that agency is tasked. The U.S. Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and similar agencies traditionally relied on that expertise to close statutory gaps and to clarify compliance and enforcement expectations through guidance, interpretive materials, and evidence-based rulemaking.
Reproductive health care is one of the areas where agency expertise has mattered most. Many federal and state laws rely on medical terms, such as “stabilizing treatment” and “emergency medical condition,” yet lawmakers rarely define what these terms mean in practice. Agencies helped fill that gap by drawing on clinical knowledge to explain how these concepts operate in real health care settings. A clear example comes from the Emergency Medical Treatment and Labor Act (EMTALA), where HHS issued guidance describing what hospitals must do to provide “stabilizing treatment” during labor emergencies, turning a general statutory requirement into concrete direction for providers.
After Chevron: Judicial Interpretation Replaces Medical Expertise
When Chevron fell, the responsibility for interpreting ambiguous statutory language shifted sharply toward the judiciary. Federal judges, who are trained as legal generalists and are no longer required to defer to evidence-based clinical standards or agency expertise, now play a much larger role in defining the contours of reproductive health care. This shift places courts at the center of decisions that once relied heavily on medical judgment for how medical terms are understood in law, how clinicians navigate emergencies, and how states implement increasingly restrictive abortion statutes.
The absence of agency interpretation also magnifies the impact of vague statutory language. Many post-Dobbs restrictive abortion laws rely on non-clinical terms, such as “serious risk,” “elective abortion,” or “late-term,” and judges must now define these concepts without the benefit of expert guidance. As a result, legal definitions may diverge from medical consensus, creating tension between clinical best practices and judicial interpretation.
This uncertainty has begun to alter clinical behavior. A growing body of research documents a rise in “hesitant medicine,” where providers delay or avoid interventions because they fear prosecution or licensing consequences. Many clinicians in restrictive states increasingly experience confusion about what care is legally permissible. The human consequences are profound. The recent case of Amber Thurman, a woman in Georgia who went 20 hours without necessary miscarriage treatment, demonstrates how legal ambiguity can translate directly into life-threatening delays at the bedside.
Legal Obligations of Agencies in the Absence of Chevron
Several long-standing legal principles still require agencies to stay actively involved in explaining the law. One is the fair-notice rule, which means that people and organizations cannot be punished for violating a standard they were never clearly told about. When laws use technical medical terms, agencies are expected to explain what they mean so that clinicians and health systems know how to comply.
Another is the Accardi principle, which requires agencies to follow their own rules. If an agency has promised to issue manuals, FAQs, or other explanatory materials to help people understand the law, it must follow through. Together, these principles show that agencies still have a crucial role in ensuring clarity, even now that courts have more power to interpret ambiguous laws.
Even without Chevron, agencies retain some level of authority to shape how reproductive health care is administered. Courts have long recognized that when Congress relies on agencies to clarify statutory terms, silence can itself create legal consequences. Under the Administrative Procedure Act, for example, a court may intervene when an agency’s failure to act undermines the statute’s basic purpose. If hospitals or clinicians cannot reasonably comply with a law because critical terms remain undefined and the procedures for satisfactory compliance are not clear, prolonged inaction may qualify as “unreasonable delay.” In addition, when an agency suddenly stops providing guidance in an area where people are already confused about what the law requires, courts can step in. Judges may decide that the agency acted unreasonably by failing to address an important problem and disrupting the expectations of those who depend on clear rules to do their jobs.
Opportunity for States and Professional Medical Associations to Fill the Guidance Gaps
As federal administrative guidance becomes less predictable, states increasingly turn to the medical profession itself to supply the standards needed to regulate care. Many states already incorporate ethical and clinical norms into licensure statutes, malpractice frameworks, and informed consent rules. These norms help define what constitutes reasonable, competent, and nondiscriminatory care when statutes rely on vague or politicized language that fails to reflect the realities of providing care in clinical settings. In practice, medical ethics is becoming a crucial source of guidance for clinicians who are trying to deliver responsible care amid evolving legal constraints.
Professional medical organizations are uniquely positioned to give clinicians the clarity they need during this period of legal uncertainty. Guidance from professional groups, such as the American Medical Association (AMA) and American College of Obstetricians and Gynecologists (ACOG), could serve as a stabilizing reference point. These groups can create practical tools that blend medical standards with explanations of how the law applies in real situations. Resources like model protocols can act as informal “safe zones” to guide emergency reproductive care when providers must act quickly. They can also issue fast, focused guidance right after major court decisions, so hospitals know how to update their policies. One such example is ACOG’s 2023 publication, “Questions to Help Hospital Systems Support and Empower Physicians in the Post-Roe Legal Landscape.”
Conclusion
The end of Chevron marks a major shift in administrative law, and its impact is felt most sharply in reproductive health care, where unclear rules can have life-or-death consequences. As judges, rather than medical experts, take on more responsibility for interpreting technical terms, clinicians are left with growing uncertainty that can slow or complicate the delivery of needed care. This creates real risks for patients and increases the likelihood that medical decisions will drift away from established clinical standards.
Even so, agencies, professional medical associations, and long-standing administrative principles still offer ways to rebuild clarity. Protecting patient safety in this new environment will require drawing on these tools and keeping medical expertise at the center, even as courts play a larger role in shaping how reproductive health care is regulated.
